NEW YORK (GenomeWeb) – DiaCarta and MIODx today said they plan to codevelop a diagnostic test to predict immunotherapy response based on MIODx's immune sequencing technology, ClonoMap.
The test will be developed and validated at DiaCarta's CLIA-certified laboratories in the San Francisco Bay Area and Nanjing, China. MIODx is an early-stage immunogenomics company based in San Jose, California, developing a T-cell receptor and B-cell receptor sequencing platform.
Financial and other terms of the deal were not disclosed.
Aiguo Zhang, founder and CEO of DiaCarta, said in a statement that MIODx's ClonoMap technology would "complement DiaCarta's well-established business in molecular diagnostics and advance a much needed test for patients undergoing immunotherapy."
Allen Northrup, CEO of MIODx, added that DiaCarta's expertise in in vitro diagnostics, as well as its CLIA-certified and ISO manufacturing facility, would help accelerate the commercialization of the ClonoMap technology, particularly in China.